Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 2 Nemolizumab Trial Opens for CPUO
2
JAK Inhibitors Show Comparable Safety to TNF Antagonists
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
Emerging Topical Alternatives to Hydroquinone in Melasma Management
5
